| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Windtree Therapeutics Inc. | Rostafuroxin | Hypertension | Phase 2b | Ongoing | Oral | Cardiology |
| Windtree Therapeutics Inc. | AEROSURF | Acute respiratory distress syndrome | Phase 2b | Withdrawn | Inhalation | Respiratory |
| Windtree Therapeutics Inc. | Istaroxime | Heart Failure | Phase 2b | Looking for Funding | Intravenous | Cardiology |
| Windtree Therapeutics Inc. | Istaroxime - (SEISMiC C) | Cardiogenic Shock in severe acute heart failure | Phase 2b | Data Released | Intravenous | Cardiology |
| Windtree Therapeutics Inc. | Lucinactant | COVID-19 / Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) | Phase 2 | Trial Planned | Intratracheal | COVID-19 |
| X4 Pharmaceuticals Inc. | Mavorixafor - (4WARD) | Chronic Neutropenia (CN) | Phase 3 | Ongoing | Oral | Hematology |
| X4 Pharmaceuticals Inc. | Mavorixafor (X4P-001) | Severe Congenital Neutropenia (SCN) | Phase 2 | Trial Completed | Oral | Genetic Disorder |
| XBiotech Inc. | Natrunix with trifluridine/tipiracil | Colorectal cancer | Phase 2/3 | oral | Oncology |